Abstract
Despite the existence of tumor-specific antigens and demonstrated presence of tumor-specific immune cells, the majority of tumors manage to avoid immune-mediated destruction. Various mechanisms have been suggested for tumor evasion from immune response. One such mechanism is thought to be mediated by transforming growth factor-β (TGF-β), an immunosuppressive cytokine found at the site of most tumors. We demonstrate here that T-cell–specific blockade of TGF-β signaling allows the generation of an immune response capable of eradicating tumors in mice challenged with live tumor cells. In addition, we provide mechanisms through which abrogation of TGF-β signaling leads to the enhancement of anti-tumor immunity. Our data indicate that T-cell–specific blockade of TGF-β signaling has strong therapeutic potential to shift the balance of the immune response in favor of anti-tumor immunity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Awwad, M. & North, R.J. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J. Exp. Med. 168, 2193–2206 (1988).
Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
Letterio, J.J. & Roberts, A.B. Regulation of immune responses by TGF-β. Annu. Rev. Immunol. 16, 137–161 (1998).
Pasche, B. Role of transforming growth factor β in cancer. J. Cell. Physiol. 186, 153–168 (2001).
van Roozendaal, C.E. et al. Transforming growth factor β secretion from primary breast cancer fibroblasts. Mol. Cell. Endocrinol. 111, 1–6 (1995).
Tamada, K. et al. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes. J. Immunol. 158, 4846–4854 (1997).
Seo, N., Tokura, Y., Takigawa, M. & Egawa, K. Depletion of IL-10– and TGF-β–producing regulatory γ δ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163, 242–249 (1999).
Chakravarthy, D., Green, A.R., Green, V.L., Kerin, M.J. & Speirs, V. Expression and secretion of TGF-β isoforms and expression of TGF-β–receptors I, II and III in normal and neoplastic human breast. Int. J. Oncol. 15, 187–194 (1999).
Maeda, H. & Shiraishi, A. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10–mediated pathways in tumor-bearing mice. J. Immunol. 156, 73–78 (1996).
Agarwal, R.K., Chan, C.C., Wiggert, B. & Caspi, R.R. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. J. Immunol. 162, 2648–2654 (1999).
Gorelik, L. & Flavell, R.A. Abrogation of TGF-β signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12, 171–181 (2000).
Nelson, B.J., Danielpour, D., Rossio, J.L., Turpin, J. & Nacy, C.A. Interleukin-2 suppresses activated macrophage intracellular killing activity by inducing macrophages to secrete TGF-β. J. Leukoc. Biol. 55, 81–90 (1994).
Lu, Z. et al. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes. J. Exp. Med. 191, 541–550 (2000).
Hung, K. et al. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188, 2357–2368 (1998).
Mombaerts, P. et al. RAG-1–deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).
Moore, M.W., Carbone, F.R. & Bevan, M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777–785 (1988).
Dal Porto, J. et al. A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc. Natl. Acad. Sci. USA 90, 6671–6675 (1993).
Lefrancois, L., Altman, J.D., Williams, K. & Olson, S. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J. Immunol. 164, 725–732 (2000).
Greenberg, N. et al. prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92, 3439–3443 (1995).
Shrikant, P., Khoruts, A. & Mescher, M.F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2–dependent mechanism. Immunity 11, 483–493 (1999).
Sotomayor, E.M., Borrello, I., Tubb, E., Allison, J.P. & Levitsky, H.I. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc. Natl. Acad. Sci. USA 96, 11476–11481 (1999).
van Elsas, A., Hurwitz, A.A. & Allison, J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).
Sullivan, T.J. et al. Lack of a role for transforming growth factor-β in cytotoxic T lymphocyte antigen-4–mediated inhibition of T cell activation. Proc. Natl. Acad. Sci. USA 98, 2587–2592 (2001).
Chen, W., Jin, W. & Wahl, S.M. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor β (TGF-β) production by murine CD4(+) T cells. J. Exp. Med. 188, 1849–1857 (1998).
Gorelik, L., Bar-Dagan, Y. & Mokyr, M.B. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J. Immunol. 156, 4298–4308 (1996).
Acknowledgements
We thank R.W. Dutton and A. Garen for gifts of tumor cell lines; J. Miller and D. Butkus for technical help; and F. Manzo for help with manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gorelik, L., Flavell, R. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 7, 1118–1122 (2001). https://doi.org/10.1038/nm1001-1118
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm1001-1118
This article is cited by
-
Dual effect of vitamin D3 on breast cancer-associated fibroblasts
BMC Cancer (2024)
-
Inactivation of TGF-β signaling in CAR-T cells
Cellular & Molecular Immunology (2024)
-
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Nature Reviews Immunology (2023)
-
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Nature Cancer (2022)
-
Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF-β degradation
Nature Communications (2022)